In the past five years, the Food and Drug Administration has approved seven new drugs for treating metastatic melanoma, the deadliest form of skin cancer. Until 2011, there were only two. These new treatments are based on discoveries in the immune system or the genome. As you’ll read in our summer issue, these new personalized treatments are extending lives far beyond patients’ original prognoses. Some feel major breakthroughs like these will help, one day, to turn a terminal illness like advanced melanoma into a chronic disease that can be managed with precision medicine.
In this issue, you can read about one young patient’s experience with melanoma, and the personalized therapy that changed her life. We also have other informative stories, including a piece on paying for personalized medicine, a feature on pharmacogenomics, and much, much more. Enjoy!